Yang Xinxin, Lin Ruiting, Feng Changzhuo, Kang Qiyuan, Yu Peng, Deng Yongzhi, Jin Ye
School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.
College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China.
Pharmaceutics. 2024 Oct 23;16(11):1353. doi: 10.3390/pharmaceutics16111353.
Diabetes is a global disease that can lead to a range of complications. Currently, the treatment of type 2 diabetes focuses on oral hypoglycemic drugs and insulin analogues. Studies have shown that drugs such as oral metformin are useful in the treatment of diabetes but can limit the liver's ability to release sugar. The development of glucose-lowering peptides has provided new options for the treatment of type 2 diabetes. Peptide drugs have low oral utilization due to their easy degradation, short half-life, and difficulty passing through the intestinal mucosa. Therefore, improving the oral utilization of peptide drugs remains an urgent problem. This paper reviews the research progress of peptide drugs in the treatment of diabetes mellitus and proposes that different types of nano-formulation carriers, such as liposomes, self-emulsifying drug delivery systems, and polymer particles, should be combined with peptide drugs for oral administration to improve their absorption in the gastrointestinal tract.
糖尿病是一种全球性疾病，可导致一系列并发症。目前，2型糖尿病的治疗主要集中在口服降糖药和胰岛素类似物上。研究表明，口服二甲双胍等药物对糖尿病治疗有效，但会限制肝脏释放糖分的能力。降血糖肽的研发为2型糖尿病的治疗提供了新的选择。肽类药物由于易于降解、半衰期短且难以穿过肠黏膜，口服利用率较低。因此，提高肽类药物的口服利用率仍然是一个紧迫的问题。本文综述了肽类药物治疗糖尿病的研究进展，并提出应将不同类型的纳米制剂载体，如脂质体、自乳化药物递送系统和聚合物颗粒，与肽类药物联合用于口服给药，以提高其在胃肠道的吸收。
